Cytochrome P450 2C9
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Cytochrome P450 2C9 as ChEMBL target CHEMBL3397, mapped to UniProt P11712. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Cytochrome P450 2C9 matters
Cytochrome P450 2C9 is reviewed as Cytochrome P450 2C9 (UniProt P11712); the current evidence base includes 90 approved drugs, 26603 compounds, and 3156 assays, with lead potency reaching pChEMBL 9.3.
Cytochrome P450 2C9 Sequence length is 490 aa.
Review this target as Cytochrome P450 2C9, mapped to UniProt P11712. Sequence length is 490 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 90 approved drugs, 26603 compounds, and 3156 assays for this target. The dominant activity type is IC50. CHEMBL16596 is the current potency anchor at pChEMBL 9.3.
Use CHEMBL16596 as the tractability anchor when discussing potency (pChEMBL 9.3).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Cytochrome P450 2C9 matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P11712, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL16596
|
9.3 | IC50 | Clinical |
|
|
No preferred name
CHEMBL220360
|
9.0 | IC50 | Clinical |
|
|
No preferred name
CHEMBL1825089
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL38958
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL1922663
|
8.8 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
RILPIVIRINE
CHEMBL175691
|
2011 |
|
|
ETRAVIRINE
CHEMBL308954
|
2008 |
|
|
RIMONABANT
CHEMBL111
|
2006 |
|
|
RITONAVIR
CHEMBL163
|
1996 |
|
|
FLUVASTATIN
CHEMBL2220442
|
1993 |
|
|
NIMODIPINE
CHEMBL1428
|
1988 |
|
|
NICARDIPINE
CHEMBL1484
|
1988 |
|
|
SULCONAZOLE
CHEMBL1221
|
1985 |
|
|
ECONAZOLE
CHEMBL808
|
1982 |
|
|
SULFAPHENAZOLE
CHEMBL1109
|
1982 |
|
|
DANAZOL
CHEMBL1479
|
1976 |
|
|
CLOTRIMAZOLE
CHEMBL104
|
1975 |
|
|
MICONAZOLE
CHEMBL91
|
1974 |
|
|
TOLBUTAMIDE
CHEMBL782
|
1961 |
|
|
TROPICAMIDE
CHEMBL1200604
|
1960 |
|
|
DICUMAROL
CHEMBL1466
|
1944 |
|
|
BENZBROMARONE
CHEMBL388590
|
— |